SH3 domain binding protein 2
Dernière mise à jour 18 Aug 2020
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
La SH3BP2 gene provides instructions for making a protein whose exact function is unclear, although it is known to interact with other proteins within cells. The SH3BP2 protein plays a role in transmitting chemical signals, particularly in certain immune system cells and cells involved in the replacement of old bone tissue with new bone (bone remodeling).
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
La SH3BP2 gene provides instructions for making a protein whose exact function is unclear, although it is known to interact with other proteins within cells. The SH3BP2 protein plays a role in transmitting chemical signals, particularly in certain immune system cells and cells involved in the replacement of old bone tissue with new bone (bone remodeling).
Studies suggest that the SH3BP2 protein helps regulate signaling pathways that turn on (activate) immune system cells called B cells and macrophages. The protein is also involved in the production of osteoclasts, which are specialized cells that break down bone tissue when it is no longer needed. Osteoclasts play a central role in bone remodeling.
Conditions referring to this gene or chromosome
Other names
3BP-2
3BP2
3BP2_HUMAN
CRBM
CRPM
FLJ42079
RES4-23
SH3-domain binding protein 2
Related patient information and medicines

Patient information leaflet
Le système immunitaire
These diseases are managed by the specialist who knows most about the system affected for that person - eg, sclérose en plaques is managed by a neurologist. What is the immune system. We are surrounded by millions of bacteria, viruses and other germs (microbes) that have the potential to enter our bodies and cause harm. The immune system is the.

Patient information leaflet
Pemphigus vulgaire
Pemphigus vulgaire est a rare skin condition that. It is a serious disease that needs treatment. If it ... These different conditions vary greatly in their seriousness, outlook (prognosis) and treatment. Pemphigus vulgaire est the most common form of pemphigus et one of le most serious blistering skin conditions. This leaflet is only about.

Patient information leaflet
Syndrome néphrotique
Nephrotic syndrome is a condition where the 'filters' in the kidney become 'leaky' and large amounts of protéines leak from the blood into the urine. The main symptom is fluid retention (oedema) which is mainly due to the low protein level in the blood. Various diseases can cause nephrotic syndrome, some more serious than others. Nephrotic syndrome.

Patient information leaflet
Puis-je prendre la crinière de lion et le matcha ensemble ?
Il y a no known harmful interactions between Lion's Mane mushroom and matcha green tea. In fact, many people combine them for a 'balanced' energy boost. However, because both substances can affect the brain and nervous system, some people may feel overly stimulated or experience a mild upset stomach. Why this happens Lion's Mane is thought to.

Patient information leaflet
Cholangite biliaire primitive
Primary biliary cholangitis (PBC) is a condition that slowly damages the bile ducts in your liver, leading to liver damage and, sometimes, liver scarring (cirrhosis). Primary biliary cholangitis (PBC) is an auto-immune condition in which your immune system gradually destroys the tiny tubes (bile ducts) which take bile from the liver to the gut.

Patient information leaflet
Puis-je prendre de la Biotine et du Tamoxifène ensemble ?
Il y a no known direct interaction between biotin and tamoxifen that would change how the médication works or increase side effects. However, high doses of biotin can interfere with certain blood tests used to monitor your health while taking tamoxifen. Always consult your GP, pharmacist, or another qualified healthcare professional before.
Lectures complémentaires et références
- SH3 domain binding protein 2; MedlinePlus, National Library of Medicine.
- Chen G, Dimitriou ID, La Rose J, Ilangumaran S, Yeh WC, Doody G, Turner M, Gommerman J, Rottapel R. The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol. 2007 Apr;27(8):3109-22. doi: 10.1128/MCB.01014-06. Epub 2007 Feb 5.
- de la Fuente MA, Kumar L, Lu B, Geha RS. 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. Mol Cell Biol. 2006 Jul;26(14):5214-25. doi: 10.1128/MCB.00087-06.
- de Lange J, van Maarle MC, van den Akker HP, Redeker EJ. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103(3):378-81. doi: 10.1016/j.tripleo.2006.05.012. Epub 2006 Sep 26. No abstract available.
- Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T, Rottapel R, Sicheri F. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell. 2011 Dec 9;147(6):1340-54. doi: 10.1016/j.cell.2011.10.046.
- Levaot N, Voytyuk O, Dimitriou I, Sircoulomb F, Chandrakumar A, Deckert M, Krzyzanowski PM, Scotter A, Gu S, Janmohamed S, Cong F, Simoncic PD, Ueki Y, La Rose J, Rottapel R. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell. 2011 Dec 9;147(6):1324-39. doi: 10.1016/j.cell.2011.10.045.
- Li CY, Yu SF. A novel mutation in the SH3BP2 gene causes cherubism: case report. BMC Med Genet. 2006 Dec 5;7:84. doi: 10.1186/1471-2350-7-84.
- Lietman SA, Kalinchinko N, Deng X, Kohanski R, Levine MA. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Hum Mutat. 2006 Jul;27(7):717-8. doi: 10.1002/humu.9433.
- Lo B, Faiyaz-Ul-Haque M, Kennedy S, Aviv R, Tsui LC, Teebi AS. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet A. 2003 Aug 15;121A(1):37-40. doi: 10.1002/ajmg.a.20226.
- Morice A, Kadlub N, Coudert A. Cherubism. 2007 Feb 26 [updated 2025 Mar 20]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1137/
- Novack DV, Faccio R. Jawing about TNF: new hope for cherubism. Cell. 2007 Jan 12;128(1):15-7. doi: 10.1016/j.cell.2006.12.019.
- Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, Onji M, Saheki Y, Kawai T, Mukherjee PM, Reichenberger E, Olsen BR. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell. 2007 Jan 12;128(1):71-83. doi: 10.1016/j.cell.2006.10.047.
- Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, Ninomiya C, doAmaral C, Peters H, Habal M, Rhee-Morris L, Doss JB, Kreiborg S, Olsen BR, Reichenberger E. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001 Jun;28(2):125-6. doi: 10.1038/88832.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

